Original articles
Heterogeneity of cell therapy products
Abstract
Cellular therapy has become a billion-dollar industry and is set to become one of the therapeutic pillars of healthcare in the 21st century. Adult stem cells, which include haematopoietic stem and progenitor cells (HSPCs) and mesenchymal stromal/stem cells (MSCs), is one of the major cell types currently under investigation for use in cell therapy. This review focuses on HSPCs and MSCs and discusses their heterogeneous nature and the problems faced in expanding these cells to therapeutic numbers for use in clinical applications.
Authors' affiliations
E Wolmarans, Institute for Cellular and Molecular Medicine, Department of Immunology and South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, South Africa
J Mellet, Institute for Cellular and Molecular Medicine, Department of Immunology and South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, South Africa
MA Ambele, Institute for Cellular and Molecular Medicine, Department of Immunology and South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, South Africa; Department of Oral Pathology and Oral Biology, Faculty of Health Sciences, University of Pretoria, South Africa
C Durandt, Institute for Cellular and Molecular Medicine, Department of Immunology and South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, South Africa
M S Pepper, Institute for Cellular and Molecular Medicine, Department of Immunology and South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, South Africa
Full Text
PDF (602KB)Cite this article
Article History
Date published: 2019-09-10
Article Views
Full text views: 1006
Comments on this article
*Read our policy for posting comments here